The FDA has approved NorthStar Medical Radioisotopes' RadioGenix System, the first isotope separation system to produce sodium pertechnetate Tc-99m from non-uranium sourced Mo-99, and the Nuclear Regulatory Commission will provide guidance for medical and commercial nuclear pharmacy users regarding the license amendments required for RadioGenix possession and use. The system "has the potential to benefit many patients as well as restore the US ability to domestically supply a critical medical diagnostic tool for the first time in 30 years," said FDA Commissioner Scott Gottlieb.